Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-Reported Social and Financial Needs: Integration in a Learning Health System.

Studies in health technology and informatics·2026
Same author

HECTOR: A Trauma Course to Match Our Population.

Irish medical journal·2026
Same author

How can we make postnatal information resources more accessible to women experiencing challenges accessing healthcare? Report of a co-production project.

International journal for equity in health·2025
Same author

The Stable Acute Vertebral (SAVe) compression fracture study.

Irish medical journal·2024
Same author

ART26.12, a novel fatty acid-binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models.

European journal of pain (London, England)·2024
Same author

What makes an athlete? A scoping review: Assessing the use of the word athlete with anterior cruciate ligament rehabilitation review studies. Is there a standard?

Scandinavian journal of medicine & science in sports·2024
Same journal

Broad-Spectrum Antibiotics are Associated with worse Survival After Radical Treatment for Glioblastoma Multiforme: A Multicentre Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Exploring the Need for Plan Adaptation in Robustly Optimised Head and Neck Intensity Modulated Proton Therapy: A Dosimetric Perspective From Initial Institutional Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Standardisation of Imaging Surveillance for Patients With Metastatic Melanoma Stopping Immune Checkpoint Inhibitors.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial's Use of Healthcare Systems Data for Clinical Follow-Up.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Autologous Cell Therapy in Oncology: Current Landscape and Future Directions.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

Related Experiment Video

Updated: Apr 3, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.8K

Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at

A Yates1, S Carroll2, A Kneebone3

  • 1Department of Radiation Oncology, The Chris O'Brien Lifehouse, Camperdown, NSW, Australia.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|September 19, 2015
PubMed
Summary
This summary is machine-generated.

Intensity-modulated radiotherapy (IMRT) for anal cancer is safe and effective, demonstrating excellent survival rates with manageable toxicity. This advanced technique shows promising results outside of clinical trials.

Keywords:
Anus neoplasmschemoradiotherapycombined modality therapyintensity-modulatedradiotherapysquamous cell

More Related Videos

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

14.5K

Related Experiment Videos

Last Updated: Apr 3, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.8K
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

14.5K

Area of Science:

  • Oncology
  • Radiotherapy
  • Cancer Treatment

Background:

  • Standard chemoradiotherapy for anal cancer presents significant acute toxicity.
  • Intensity-modulated radiotherapy (IMRT) offers a potential method to mitigate these treatment-related side effects.

Purpose of the Study:

  • To evaluate the implementation and outcomes of IMRT with simultaneous integrated boost for anal cancer treatment.
  • To assess the safety, toxicity, and efficacy of this IMRT approach in an unselected patient population.

Main Methods:

  • Retrospective collection of acute toxicity data from patients treated with IMRT between January 2008 and December 2011.
  • Concurrent chemotherapy with 5-fluorouracil and mitomycin-C, with radiotherapy doses adjusted per RTOG 0529 protocol.
  • Analysis of locoregional control and survival outcomes with a median follow-up of 43 months.

Main Results:

  • High 3-year survival rates: 94% locoregional control, 92% overall survival, 89% disease-free survival.
  • Low rates of severe acute toxicity: no grade 4 toxicity, with grade 3 rates of 33% dermatological, 14% gastrointestinal, and 19% hematological.
  • Successful achievement of RTOG 0529 dose specifications for most critical organs, despite minor deviations in small bowel constraints.

Conclusions:

  • IMRT with simultaneous integrated boost is a safe and well-tolerated treatment for anal cancer in a general patient population.
  • The technique allows for achievable dose specifications and excellent locoregional control and survival outcomes.
  • These findings support the use of IMRT for anal cancer treatment outside of clinical trial settings.